BDN vs REAX

The Advanced Deterministic Scorecard reveals severe financial health concerns with a Piotroski F-Score of just 2/9, indicating weak fundamental strength. Despite a low Price/Book ratio of 0.63 and a high dividend yield of 15.18%, the company is unprofitable with a -46.10% profit margin and negative ROE of -19.12%. Earnings have consistently missed estimates over the last four quarters by an average of -41.6%, while insider selling and a bearish technical trend reinforce negative sentiment. The stock trades below analyst target of $4.34, but persistent losses and an unsustainable payout ratio of 542.86% raise serious sustainability concerns.

REAX exhibits a stark divergence between fundamental health and growth potential. The deterministic baseline is weak, highlighted by a Piotroski F-Score of 2/9, indicating significant financial instability and poor operational efficiency. However, the company maintains strong top-line momentum with 44.10% YoY revenue growth and a very low Price/Sales ratio of 0.30. While analysts remain aggressively bullish with a target of $5.35, the technical trend is bearish and profitability remains elusive.